Pds Biotechnology Corporation2024财年第三财季实现净利润-10.73百万美元，同比增加1.11%

市场透视00:02

11月23日，Pds Biotechnology Corporation（PDSB.US）公布财报，公告显示公司2024财年第三财季净利润为-10.73百万美元，同比增加1.11%；其中营业收入为0.00美元，每股基本收益为-0.29美元。从资产负债表来看，Pds Biotechnology Corporation（PDSB.US）总负债30.45百万美元，其中短期债务12.56百万美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485298722?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485298722","market":"us","top_or_hot":-1,"title":"Pds Biotechnology Corporation2024财年第三财季实现净利润-10.73百万美元，同比增加1.11%","media":"市场透视","content":"<div>\n<p>11月23日，Pds Biotechnology Corporation（PDSB.US）公布财报，公告显示公司2024财年第三财季净利润为-10.73百万美元，同比增加1.11%；其中营业收入为0.00美元，每股基本收益为-0.29美元。从资产负债表来看，Pds Biotechnology Corporation（PDSB.US）总负债30.45百万美元，其中短期债务12.56百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000318a24e499a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pds Biotechnology Corporation2024财年第三财季实现净利润-10.73百万美元，同比增加1.11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPds Biotechnology Corporation2024财年第三财季实现净利润-10.73百万美元，同比增加1.11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000318a24e499a&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Pds Biotechnology Corporation（PDSB.US）公布财报，公告显示公司2024财年第三财季净利润为-10.73百万美元，同比增加1.11%；其中营业收入为0.00美元，每股基本收益为-0.29美元。从资产负债表来看，Pds Biotechnology Corporation（PDSB.US）总负债30.45百万美元，其中短期债务12.56百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000318a24e499a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PDSB","symbol_name":"PDS Biotechnology Corporation","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000318a24e499a&s=b","article_id":"2485298722","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000318a24e499a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485298722","pubTimestamp":1732291378,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Pds Biotechnology Corporation公布财报，公告显示公司2024财年第三财季净利润为-10.73百万美元，同比增加1.11%；其中营业收入为0.00美元，每股基本收益为-0.29美元。从资产负债表来看，Pds Biotechnology Corporation总负债30.45百万美元，其中短期债务12.56百万美元，资产负债比为1.73，流动比率为2.85。机构评级：截至2024年11月23日，当前有5家机构对Pds Biotechnology Corporation目标价做出预测，其中目标均价为11.90美元，其中最低目标价为4.50美元，最高目标价为21.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PDSB":"PDS Biotechnology Corporation"},"translate_title":"Pds Biotechnology Corporation achieved net profit of-US $10.73 million in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 1.11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PDSB":0.9},"content_text":"11月23日，Pds Biotechnology Corporation（PDSB.US）公布财报，公告显示公司2024财年第三财季净利润为-10.73百万美元，同比增加1.11%；其中营业收入为0.00美元，每股基本收益为-0.29美元。从资产负债表来看，Pds Biotechnology Corporation（PDSB.US）总负债30.45百万美元，其中短期债务12.56百万美元，资产负债比为1.73，流动比率为2.85。机构评级：截至2024年11月23日，当前有5家机构对Pds Biotechnology Corporation目标价做出预测，其中目标均价为11.90美元，其中最低目标价为4.50美元，最高目标价为21.00美元。公司简介：PDS Biotechnology Corp 是一家临床阶段的生物技术公司，主要在美国从事药物研发。 它从事各种早期和晚期癌症的治疗，包括头颈癌、前列腺癌、乳腺癌、宫颈癌、肛门癌和其他癌症。 其产品基于专有的Versamune平台技术，该技术可激活并引导人体免疫系统对癌细胞发动强大而有针对性的攻击。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485298722"}